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Abstract Conjugates of anti-CD25 monoclonal antibodies 
against cell surface IL-2 receptor with MLIA and RTA were 
prepared and investigated. Both of the immunotoxins had high 
specific cytotoxic activity on target cells. The ICso value of the 
anti-CD25/MLIA immunotoxin was 15-fold greater than that of 
the anti-CD25/RTA. Previous studies of the anti-CD5 immuno- 
toxins with MLIA and RTA showed that the anti-CD5/MLIA IT 
was 80-fold more active than anti-CD5/RTA IT [Tonevitsky et 
al. (1991) Int. J. Immunopharmacol. 13, 1037-1041]. The 
surface hydrophobicity of the MLI A-chain was 4-fold higher 
than that of the ricin A-chain as estimated by binding with ANS. 
In model experiments with small unilamellar DMPC liposomes, 
MLIA but not RTA increased the turbidity of liposome 
suspensions at pH 4.5. Our results indicate that the greater 
cytotoxic activity of the MLI A-chain immunotoxin probably 
provided a higher surface hydrophobicity of the protein and the 
ability to interact with phospholipid membranes. 
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1. Introduction 
Immunotoxins are conjugates in which cell-binding ligands 
are coupled to toxins or their subunits. If the ligand is cell- 
specific monoclonal antibody immunotoxin should selectively 
kill target cells in tissue cultures. Plant and bacterial toxins or 
their enzymatically active parts have been used for prepara- 
tion of immunotoxins [2]. One of the problems involved in the 
clinical use of immunotoxins i the lower activity of A-chain 
immunotoxins as compared to the native toxins. 
Ricin from Ricinus communis and mistletoe lectin I (MLI) 
from Viscum album are toxic glycoproteins from the RIP with 
a molecular mass of 63 kDa which consists of two disulfide- 
linked subunits [3]. The B-chain (34 kDa) is a lectin with two 
galactose-binding sites [4]. The A-chain (27 kDa) is a highly 
specific N-glycosidase which passes into the cytosol and cata- 
lytically inactivates protein synthesis [5]. The structure and 
mechanism of action of ricin and MLI  are similar to those 
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of other ribosome-inactivating proteins of type II (abrin, 
modecin and volkensin) [6]. It has previously been shown 
that immunotoxins with the MLI  A-chain are about 50-fold 
more active than ricin A-chain conjugates [1,7]. 
In the present paper, we have compared the cytotoxic ac- 
tivity of immunotoxins with the A-chain of ricin or mistletoe 
lectin I and anti-CD25 monoclonal antibody against IL-2 re- 
ceptor. We also investigated the ability of A-chains to interact 
with model phospholipid membranes and the hydrophobic 
probe ANS. 
2. Materials and methods 
Sepharose CL-6B, Sepharose 4B, N-succinimidyl-3-(2-pyridyl- 
dithio)propionate (SPDP), and dithiotreitol (DTT) were obtained 
from LKB-Pharmacia (Sweden); cell culture medium RPMI 1640, 
L-glutamine, kanamycin and fetal calf serum (FCS) were from Flow 
Labs (UK); all other reagents came from Sigma (USA). Anti-CD25 
(IgG1) monAB was kindly provided by J. Kopp and I.J. Korner (Max 
Delbruck Centrum for Molecular Medicine, Berlin-Buch, Germany). 
2.1. Isolation of toxins and their subunits 
MLI was isolated from V. album according to [3]. MLI A-subunit 
was purified using affinity chromatography. 25mg of MLI were ap- 
plied on a 4B lactosyl-Sepharose column (5 ml) and washed using 25 
ml PBS. MLIA was eluted with 300 ml of 2% mercaptoethanol in PBS 
(rate: 0.15 ml/min). MLIA was dialyzed and concentrated on an 
Amicon concentrating unit. 
Ricin was purified from R. communis eeds according to [8]. Ricin 
A-chain was isolated as previously described [8]. The toxin A-subunit 
preparation was additionally purified from RTB on Sepharose 4B 
with fixed asialofetuin. 
2.2. Preparation of immunotoxins and cytotoxic activity determination 
The conjugates of monoclonal antibodies and toxin A-chains were 
prepared by using SPDP as previously described [9]. Briefly, 5 mg 
antibody (5 mg/ml) was dialyzed against 0.1 M sodium phosphate, 
pH 7.5, which contained 0.1 M NaC1 for a period of 16 h. A 10-fold 
molar excess of SPDP was added, and the solution was allowed to 
stand at room temperature for 30 min followed by gel filtration on a 
PD-10 column (LKB-Pharmacia, Sweden), equilibrated with the same 
buffer. The number of PDP groups per molecule of monAB was 3.3.4 
mg ricin or MLI A-chain (2 mg/ml) was reduced with 10 mM DTT 
for 10 min and passed over a Sephadex G-25 column in buffer con- 
taining 0.1 M NaCI, 0.1 M sodium phosphate, pH 7.5. Freshly re- 
duced A-chain was immediately mixed with PDP antibody. This mix- 
ture was incubated at room temperature for 30 min and concentrated. 
The prepared conjugate was separated from unreacted A-chain by gel 
filtration on Sepharose CL-6B. Proteins were analyzed by SDS-PAGE 
with and without reduction according to [10]. After staining, gels were 
scanned using an Ultroscan-2202 (LKB-Pharmacia, Sweden). The 
average number of A-chain molecules per antibody molecule varied 
from 2.0 to 2.2. 
Cytotoxic activity of immunotoxins was assessed on inhibition of 
[3H]thymidine incorporation into human activated lymphocytes as 
described [11]. 
All rights reserved. 
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2..:. Determ&ation of protein interaction with liposomes and ANS 
Small unilamellar liposomes were produced by drying of dimyris- 
toylphosphatidylcholine (DMPC) on a rotor evaporator. Subse- 
quently, the mixture was subjected to ultrasonic treatment for 5 min 
in a buffer containing 5 mM TES, 140 mM NaCI, 1 mM EDTA, at 
ptl 7.5 under a nitrogen atmosphere (50 W, 22-28 kHz) at +4°C and 
incubated for 2 h at +28°C. Phase transition and liposome aggrega- 
tic,n were monitored via optical density measurements at a wavelength 
o! 350 nm using a UV-Vis spectrophotometer (Perkin & Elmer, Ger- 
mmy) as previously described [14]. The concentration of lipids in the 
liposome solution was 5 mM in phase transition experiments and 250 
m Vl in aggregation experiments, All liposome aggregation experi- 
re,rots were carried out at 28°C. 
Binding of 1-anilinenaphtalene-8-sulfonate (ANS) to toxin subunits 
w.ts determined as described in [12]. 
3. Resu l ts  and d iscuss ion 
The cytotoxic activity of the immunotoxins containing anti- 
(D25 monAB and MLIA or RTA is shown in Fig. 1. The 
Its'50 for MLIA-IT is 2.0×10 -t° M and 4.0×10 -9 M for 
R TA-IT. Previously, it was shown that the ICs0 of isolated 
R TA and MLIA was more than l0 -s M [1]. Therefore, ITs 
have high specific cytotoxic activity. 
The ICs0 of IT consisting of anti-CD5 monAB and MLIA 
as more than 80 times that of IT with the same monAB and 
I~TA [1]. The enzymatic activity of these subunits does not 
dffer in cell-free systems [13]. Both chains have identical car- 
b.)hydrate components [14,15], therefore differences in IT ac- 
t~ city cannot be accounted for by interaction with non-galac- 
t~,se-specific receptors. MLIA probably has structural 
p,.~culiarities that are important in the intracellular pathway 
i~,cluding subunit translocation to the cytosol. 
The data on ANS binding with enzymatic subunits howed 
ttat  the association constant of ANS with MLIA and RTA is 
3 6×107 M -~. The high value of the association constant 
n .eans that A-chains of the plant toxins have highly hydro- 
!caobic domains [12]. The maximum number of binding sites 
f )r ANS in the case of RTA was l, and 4 for MLIA. MLIA 
c m bind more effectively with hydrophobic sites of intracel- 
1 dar membranes before translocation i to the cytosol. 
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,b-" ,b -'° ,b -~ tb-" 
I T  cortcc, n t ra t ion ,  [M] 
t ig. 1. Cytotoxic activity of anti-CD25/RTA immunotoxin (1), anti- 
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Fig. 2. Phase transition of DMPC-liposomes at pH 4.5. 1, without 
proteins; 2, in the presence of RTA; 3, in the presence of MLIA. 
ITs and holotoxins are internalized via a receptor-mediated 
pathway [16]. After binding with receptors, the conjugates 
progress to intracellular compartments with different pH (en- 
dosomes, lysosomes, cis- and trans-Golgi). Ricin reaches the 
endoplasmic reticulum before undergoing translocation to the 
cytoplasm [17]. Apparently, MLI also reach the Golgi appa- 
ratus before translocation of A-chain to the cytoplasm [18]. 
Therefore, the A-subunit reaches ribosomes via retrograde 
transport. This pathway depends on protein-protein a d pro- 
tein-lipid interactions. We performed model experiments for 
investigation of protein interactions with phospholipid mem- 
branes at different pH values. Holotoxins and their subunits 
did not influence the phase transition of DMPC liposomes 
(data not shown). Fig. 2 shows the effect of RTA and 
MLIA on the phase transition at pH 4.5. In the presence of 
MLIA at acid pH, increasing D350 of the liposome suspension 
was observed at the temperature of the phase transition. It is 
possible that the MLIA molecule can undergo a conforma- 
tional change at pH 4.5 and at the moment of phase transition 
interact with the disordered phospholipid bilayer. The influ- 
ence of the proteins on liposome size was investigated at a 
temperature above the phase transition (28°C, liquid crystal 
for DMPC). At acid pH, MLIA increased the D350 of the 
liposome suspension, i.e. the size of phospholipid particles 
was increased (Fig. 3). Apparently, at pH 4.5 in the MLIA 
molecule, two hydrophobic sites are exposed as the minimum 
number that can interact with liposomes. 
Protein-lipid interactions depend on protein structure and 
bilayer composition. Obviously, the effectiveness of the A- 
chain interaction with the bilayer is very important for protein 
translocation. Our data suggest hat MLIA more effectively 
interacts with phospholipid bilayers than RTA. It was pre- 
viously demonstrated using an intrinsic fluorescence method 
that the structure and stability of these subunits are practi- 
cally identical [19,20]. IT with two molecules of ricin A-chain 
had more cytotoxic activity than IT with one RTA [21]. An 
increase in the hydrophobicity of the toxic part can increase 
the cytotoxicity of a conjugate. The high activity of ITs con- 
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taining MLIA is accounted for by their highly hydrophobic 
nature and ability to interact with model phospholipid mem- 
branes. We suggest hat the A-chain of MLI is a very promis- 
ing candidate for the design of immunotoxins. 
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